JP2014504297A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504297A5 JP2014504297A5 JP2013545118A JP2013545118A JP2014504297A5 JP 2014504297 A5 JP2014504297 A5 JP 2014504297A5 JP 2013545118 A JP2013545118 A JP 2013545118A JP 2013545118 A JP2013545118 A JP 2013545118A JP 2014504297 A5 JP2014504297 A5 JP 2014504297A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oprf
- fusion protein
- cys27
- cys18
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 239000003153 chemical reaction reagent Substances 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000002163 immunogen Effects 0.000 claims 6
- 239000008196 pharmacological composition Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 230000006334 disulfide bridging Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426760P | 2010-12-23 | 2010-12-23 | |
| US61/426,760 | 2010-12-23 | ||
| PCT/EP2011/054127 WO2012084272A1 (en) | 2010-12-23 | 2011-03-18 | Oprf/i agents and their use in hospitalized and other patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032315A Division JP2016147867A (ja) | 2010-12-23 | 2016-02-23 | Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504297A JP2014504297A (ja) | 2014-02-20 |
| JP2014504297A5 true JP2014504297A5 (enExample) | 2014-04-17 |
| JP5893640B2 JP5893640B2 (ja) | 2016-03-23 |
Family
ID=44210049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013545118A Expired - Fee Related JP5893640B2 (ja) | 2010-12-23 | 2011-03-18 | Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 |
| JP2016032315A Pending JP2016147867A (ja) | 2010-12-23 | 2016-02-23 | Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032315A Pending JP2016147867A (ja) | 2010-12-23 | 2016-02-23 | Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130266575A1 (enExample) |
| EP (1) | EP2655402A1 (enExample) |
| JP (2) | JP5893640B2 (enExample) |
| KR (1) | KR20130133212A (enExample) |
| CN (1) | CN103270047A (enExample) |
| AU (1) | AU2011348396A1 (enExample) |
| BR (1) | BR112013016254A2 (enExample) |
| CA (1) | CA2822684A1 (enExample) |
| MX (1) | MX2013007146A (enExample) |
| WO (1) | WO2012084272A1 (enExample) |
| ZA (1) | ZA201304235B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2892688A1 (en) | 2012-11-30 | 2014-06-05 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations |
| CN103983793A (zh) * | 2014-05-29 | 2014-08-13 | 上海理工大学 | 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法 |
| AU2015308625A1 (en) * | 2014-08-29 | 2017-04-20 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind OprF and Oprl |
| NZ774893A (en) * | 2015-05-01 | 2024-11-29 | Inhibrx Biosciences Inc | Type iii secretion system targeting molecules |
| WO2016193402A1 (en) | 2015-06-03 | 2016-12-08 | Valneva Austria Gmbh | Pseudomonas vaccine |
| PL3322734T3 (pl) | 2015-07-16 | 2021-05-04 | Inhibrx, Inc. | Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5 |
| FR3099160B1 (fr) * | 2019-07-23 | 2022-05-06 | Univ Grenoble Alpes | Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant |
| WO2023236041A1 (zh) * | 2022-06-07 | 2023-12-14 | 南方科技大学 | 编码PcrV和/或OprF-I蛋白的mRNA疫苗 |
| CN116251178A (zh) * | 2023-03-28 | 2023-06-13 | 吉林农业大学 | 一种铜绿假单胞菌疫苗及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494672A (en) * | 1989-04-28 | 1996-02-27 | S.P.I. Synthetic Peptides Incorporated | Pseudomonas peptide composition and method |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| ATE190657T1 (de) | 1994-12-16 | 2000-04-15 | Chiron Behring Gmbh & Co | Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| EP1423129A1 (en) * | 2001-09-03 | 2004-06-02 | Anbics Patents-Licences AG | Therapeutic process for p. aeruginosa infections using macrolide antibiotics |
| CA2466474C (en) * | 2001-11-13 | 2012-10-09 | Shire Biochem Inc. | Compositions comprising spa-1, spa-2 and spa-3, polypeptides and related uses |
| CA2513701C (en) * | 2003-01-15 | 2013-06-18 | Haruo Sugiyama | Dimerized peptide |
| EP1623229A2 (en) | 2003-05-15 | 2006-02-08 | Cytos Biotechnology AG | Selection of b cells with specificity of interest: method of preparation and use |
| GB0410958D0 (en) * | 2004-05-15 | 2004-06-16 | Haptogen Ltd | Methods for reducing biofilm formation in infectious bacteria |
| UA91205C2 (ru) * | 2004-12-17 | 2010-07-12 | Венус Ремедиз Лимитед | Антибиотическая комбинация амикацина и цефепима для создания общего раствора для лечения инфекций |
| EP1921142A1 (en) | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| CA2892688A1 (en) * | 2012-11-30 | 2014-06-05 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations |
-
2011
- 2011-03-18 CA CA2822684A patent/CA2822684A1/en not_active Abandoned
- 2011-03-18 CN CN2011800625695A patent/CN103270047A/zh active Pending
- 2011-03-18 WO PCT/EP2011/054127 patent/WO2012084272A1/en not_active Ceased
- 2011-03-18 JP JP2013545118A patent/JP5893640B2/ja not_active Expired - Fee Related
- 2011-03-18 AU AU2011348396A patent/AU2011348396A1/en not_active Abandoned
- 2011-03-18 MX MX2013007146A patent/MX2013007146A/es not_active Application Discontinuation
- 2011-03-18 KR KR1020137015420A patent/KR20130133212A/ko not_active Ceased
- 2011-03-18 EP EP11714502.9A patent/EP2655402A1/en not_active Withdrawn
- 2011-03-18 BR BR112013016254A patent/BR112013016254A2/pt not_active IP Right Cessation
-
2013
- 2013-03-12 US US13/795,448 patent/US20130266575A1/en not_active Abandoned
- 2013-06-10 ZA ZA2013/04235A patent/ZA201304235B/en unknown
-
2016
- 2016-02-23 JP JP2016032315A patent/JP2016147867A/ja active Pending